In a mouse pancreatic cancer model, inhibition of IL‐17‐stimulated NETosis has shown potent anti‐cancer effects and enhances sensitivity to ICIs (PD1, CTLA4) [61]. Here, CTLA4 is linked to pancreatic neoplasm.